Pancreatic Cancer Research

ResearcherNara Medical UniversityNo recent work listed

Kenji Nakagawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9171-9448; OpenAlex author ID A5010727612. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2018: 1 paper · 2019: 4 papers · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper

Papers 12

  1. Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-022-02057-1↗
  2. Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer. Co-author DOI 10.1007/s10147-022-02131-x↗
  3. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33284↗
  4. Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential. Co-author DOI 10.1016/j.pan.2021.01.013↗
  5. Does direct invasion of peripancreatic lymph nodes impact survival in patients with pancreatic ductal adenocarcinoma? A retrospective dual-center study. Co-author DOI 10.1016/j.pan.2021.03.008↗
  6. Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma? First author DOI 10.3390/jcm10040873↗
  7. Application of liquid biopsy for surgical management of pancreatic cancer. Co-author DOI 10.1002/ags3.12317↗
  8. Risk Factors for Late-Onset Gastrointestinal Hemorrhage After Pancreatoduodenectomy for Pancreatic Cancer. Co-author DOI 10.1007/s00268-018-4791-7↗
  9. A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Ca… Co-author DOI 10.1007/s00268-018-4820-6↗
  10. Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.05.461↗
  11. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2018-0900↗
  12. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-018-1709-7↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Sho · 12 shared papers, 2018–2023 · strength 1.39
  2. Minako Nagai · 11 shared papers, 2018–2023 · strength 1.25
  3. Kota Nakamura · 10 shared papers, 2018–2023 · strength 1.12
  4. Takahiro Akahori · 10 shared papers, 2018–2021 · strength 1.07
  5. Satoshi Nishiwada · 8 shared papers, 2018–2023 · strength 0.90
  6. Naoya Ikeda · 7 shared papers, 2018–2021 · strength 0.67
  7. Tadataka Takagi · 5 shared papers, 2019–2021 · strength 0.59
  8. Taichi Terai · 4 shared papers, 2021–2023 · strength 0.56
  9. Kimihiko Kichikawa · 4 shared papers, 2018–2019 · strength 0.34
  10. Toshihiro Tanaka · 4 shared papers, 2018–2019 · strength 0.34
  11. Kensuke Yamamura · 2 shared papers, 2021–2023 · strength 0.28
  12. Ajay Goel · 2 shared papers, 2021–2023 · strength 0.28
  13. So Yamaki · 2 shared papers, 2019–2021 · strength 0.20
  14. Sohei Satoi · 2 shared papers, 2019–2021 · strength 0.20
  15. Tomohisa Yamamoto · 2 shared papers, 2019–2021 · strength 0.20
  16. Hideyuki Nishiofuku · 2 shared papers, 2019 · strength 0.18
  17. Suguru Yamada · 1 shared paper, 2023 · strength 0.17
  18. Yasuhiro Kodera · 1 shared paper, 2023 · strength 0.17
  19. Tsutomu Fujii · 1 shared paper, 2023 · strength 0.17
  20. Chiho Ohbayashi · 2 shared papers, 2018–2019 · strength 0.16
  21. Toshihide Sasaki · 1 shared paper, 2022 · strength 0.15
  22. Satoshi Yasuda · 1 shared paper, 2022 · strength 0.15
  23. Joon Seong Park · 1 shared paper, 2021 · strength 0.14
  24. Hyung Sun Kim · 1 shared paper, 2021 · strength 0.14
  25. Dong Sup Yoon · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.